TScan Therapeutics, Inc.
TCRX
NASDAQ·Healthcare·Biotechnology·Mkt cap $23.9M
$0.39
▲ +5.55%
P/E
—
Mkt Cap
$23.9M
52-Wk Range
$0.35–$2.57
52-Week Range
$0.35 - $2.57
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 79.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Value
Valuation data unavailable
Momentum
Falling
-60.1% over 3m
Quality
Excellent
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying TCRX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 12, 2026
Reported EPS of -$0.23 vs -$0.25 consensus (+9.2% surprise). Revenue of $1.1M vs $1.9M expected (-44.0%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+9.2%
Revenue trend · last 2Q
—
-66%
Q1 26
Q2 26
$982.0K
$1.1M
Margins · last 2Q
Gross
100.0%
Profit
-2888.6%
Wall Street consensus
2 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Needham · Sep 2, 2026
vs Industry
How TCRX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.